Sungmoo Kim

Title: The Innovations of Sungmoo Kim

Introduction

Sungmoo Kim is a notable inventor based in Seongnam, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific cancer pathways. His work focuses on creating effective treatments for diseases mediated by AXL, Mer, and c-Met.

Latest Patents

Sungmoo Kim holds a patent for "Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof." This patent describes an inhibitor of AXL, Mer, and/or c-Met, which can be represented by a specific formula. The compound is designed to treat or prevent diseases associated with these targets, particularly in re-sensitizing cancer cells that have developed resistance to anti-cancer agents.

Career Highlights

Sungmoo Kim is associated with Cmg Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His research has the potential to impact the treatment of various cancers, making him a key figure in the industry.

Collaborations

Some of his coworkers include Jin Sung Kim and Young Sang Kim, who contribute to the collaborative efforts at Cmg Pharmaceutical Co., Ltd. Their combined expertise enhances the research and development initiatives within the company.

Conclusion

Sungmoo Kim's work exemplifies the critical role of innovation in the pharmaceutical industry. His contributions to cancer treatment through targeted inhibitors highlight the importance of research in developing effective therapies.